F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, 514F RMB, 143 Graham Avenue, Lexington, KY, USA.
Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Mol Imaging Biol. 2022 Apr;24(2):208-219. doi: 10.1007/s11307-021-01648-3. Epub 2021 Oct 27.
Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.
缺氧是大多数实体瘤的一个关键预后指标，因为它与肿瘤血管生成、转移、复发和对治疗的反应有关。准确测量和绘制肿瘤氧合状态图，并在干预后进行监测，可以促进疾病进展评估，并有助于治疗计划。目前，尚无非侵入性时空测量缺氧的金标准。磁共振成像（MRI）是一种很有吸引力的选择，因为它是一种临床可用的非电离成像方式。具体来说，可以将全氟化碳（PFC）示踪剂引入肿瘤组织，利用其自旋晶格弛豫率（R1）与局部氧分压（pO）的线性关系，实时监测体内组织的氧合状态。在这篇综述中，我们将重点介绍氟-19 MRI 和光谱（MRS）在评估肿瘤血氧饱和度和治疗反应方面的早期研究和最新进展。
